These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16420051)

  • 1. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
    Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
    J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
    Wendt MD; Shen W; Kunzer A; McClellan WJ; Bruncko M; Oost TK; Ding H; Joseph MK; Zhang H; Nimmer PM; Ng SC; Shoemaker AR; Petros AM; Oleksijew A; Marsh K; Bauch J; Oltersdorf T; Belli BA; Martineau D; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2006 Feb; 49(3):1165-81. PubMed ID: 16451081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
    Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
    J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based deconstruction of Bcl-xL inhibitors.
    Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
    J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
    Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
    J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
    Mukherjee P; Desai P; Zhou YD; Avery M
    J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.
    Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D
    J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.
    Melkko S; Mannocci L; Dumelin CE; Villa A; Sommavilla R; Zhang Y; Grütter MG; Keller N; Jermutus L; Jackson RH; Scheuermann J; Neri D
    ChemMedChem; 2010 Apr; 5(4):584-90. PubMed ID: 20229565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
    Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
    J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new assay for the discovery of Bcl-XL inhibitors.
    Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
    Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
    Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
    J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
    Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
    Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
    Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK
    Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
    Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
    Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
    J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
    Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
    J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
    Petros AM; Huth JR; Oost T; Park CM; Ding H; Wang X; Zhang H; Nimmer P; Mendoza R; Sun C; Mack J; Walter K; Dorwin S; Gramling E; Ladror U; Rosenberg SH; Elmore SW; Fesik SW; Hajduk PJ
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6587-91. PubMed ID: 20870405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.